| Serial Number | 79160465 |
| Word Mark | PETIZATION |
| Filing Date | Wednesday, August 27, 2014 |
| Status | 404 - IR CANCELLED - US REGISTRATION CANCELLED |
| Status Date | Tuesday, August 27, 2024 |
| Registration Number | 4879066 |
| Registration Date | Tuesday, January 5, 2016 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 20, 2015 |
| Goods and Services | Biological preparations for pharmaceutical purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for animals for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; radioactive preparations for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; reagents for in-vitro laboratory use for medical diagnostic veterinary purposes; reagents for laboratory purposes for medical diagnostic veterinary purposes; reagents for use in analytical tests for medical diagnostic veterinary purposes; reagents for use in diagnostic tests for medical diagnostic veterinary purposes; reagents for use in the development of monoclonal antibodies for medical diagnostic veterinary purposes; reagents in kit form for conducting enzyme-linked immunosorbent assays (ELISA) for medical diagnostic veterinary purposes; veterinary preparations for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary preparations for administration by injection for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary preparations for immunisation against disease; veterinary preparations for use in improving the skin; veterinary preparations for use in treating the coat; veterinary preparations in dosage forms for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary products, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues; veterinary products for equines, namely, fully equinized monoclonal antibodies, equine fusion proteins; veterinary vaccines; biological preparations for veterinary purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; antibodies for pain, itch, diabetes, cancer, and inflammation; immunological antibodies for medical use for the treatment of cancer; monoclonal antibodies for medical diagnostic use; monoclonal antibodies for medical use for pain, itch, diabetes, cancer, and inflammation; monoclonal antibodies for therapeutic purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; products containing antibodies for use in medicine for pain, itch, diabetes, cancer, and inflammation; reagents for use in the development of monoclonal antibodies for medical diagnostic purposes; monoclonal antibodies for medical use for diagnostic purposes for pain, itch, diabetes, cancer and inflammation; biological preparations for medical purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; biological products for medical use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; biological reagents for medical diagnostic purposes for use in molecular biology; biological substances for medical use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; reagents for use in biological processing for medical diagnostic purposes; reagents for use in biological processing for medical diagnostic purposes for veterinary purposes; therapeutic biological products, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; monoclonal antibody reagents for medical diagnostic use; medical therapeutic agents for the treatment of pain, itch, diabetes, cancer, and inflammation; medical therapeutic drugs for the treatment of pain, itch, diabetes, cancer, and inflammation; animal care products for veterinary use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues or recombinant proteins for the treatment of pain, itch, diabetes, cancer, and inflammation; biotechnological preparations for veterinary use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation |
| Goods and Services | Pharmaceutical research services; research relating to pharmaceuticals; services for assessing the efficiency of pharmaceuticals, namely, molecular binding, stability, immunogenicity and potency assays; services for assessing the safety of pharmaceuticals, namely, animal model and in-species clinical studies; services for assessing the efficiency of veterinary drugs, namely, molecular binding, stability, immunogenicity and potency assays and proof-of-concept and field studies; veterinary laboratory services; advisory services relating to scientific research, namely, advice in the field of therapeutic biologic drug candidate selection and development; laboratory services, namely, laboratory services for scientific research services and analysis of therapeutic biologic drugs; scientific laboratory services; scientific research; scientific research in the field of pharmacy; biological research; services for assessing the safety of veterinary drugs, namely, animal model and in-species clinical studies; provision of information relating to scientific research, namely, information on the identification and development of therapeutic biologic drug candidates |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | F - NOT AVAILABLE |
| Class Status Date | Friday, July 22, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | F - NOT AVAILABLE |
| Class Status Date | Friday, July 22, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Zoetis Services LLC |
| Party Type | 32 - New Owner After Registration |
| Legal Entity Type | 99 - Other |
| Address | US |
| Party Name | NEXVET AUSTRALIA PTY LTD |
| Party Type | 31 - New Owner After Registration |
| Legal Entity Type | 98 - Unknown |
| Address | AU |
| Party Name | NVIP Pty Ltd |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 11 - Company |
| Address | AU |
| Party Name | NVIP Pty Ltd |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 11 - Company |
| Address | AU |
| Party Name | NVIP Pty Ltd |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 11 - Company |
| Address | AU |
| Event Date | Event Description |
| Friday, February 20, 2015 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Monday, February 23, 2015 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, February 23, 2015 | ASSIGNED TO EXAMINER |
| Wednesday, February 25, 2015 | NON-FINAL ACTION WRITTEN |
| Thursday, February 26, 2015 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, February 26, 2015 | REFUSAL PROCESSED BY MPU |
| Thursday, February 26, 2015 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, February 27, 2015 | APPLICATION FILING RECEIPT MAILED |
| Friday, March 13, 2015 | REFUSAL PROCESSED BY IB |
| Tuesday, August 18, 2015 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, August 18, 2015 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, August 18, 2015 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, August 20, 2015 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, September 14, 2015 | ASSIGNED TO LIE |
| Wednesday, September 16, 2015 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Wednesday, September 30, 2015 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, September 30, 2015 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, September 30, 2015 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Saturday, October 17, 2015 | NOTIFICATION PROCESSED BY IB |
| Tuesday, October 20, 2015 | PUBLISHED FOR OPPOSITION |
| Tuesday, October 20, 2015 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, January 5, 2016 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, April 5, 2016 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Thursday, April 7, 2016 | FINAL DISPOSITION PROCESSED |
| Thursday, April 7, 2016 | FINAL DISPOSITION NOTICE SENT TO IB |
| Friday, July 8, 2016 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Friday, December 30, 2016 | CHANGE OF OWNER RECEIVED FROM IB |
| Saturday, January 2, 2021 | NEW REPRESENTATIVE AT IB RECEIVED |
| Tuesday, January 5, 2021 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Friday, September 24, 2021 | CHANGE OF OWNER RECEIVED FROM IB |
| Friday, July 22, 2022 | CANCELLED SECTION 71 |
| Wednesday, March 22, 2023 | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED |
| Sunday, April 30, 2023 | INVALIDATION PROCESSED |
| Monday, May 1, 2023 | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB |
| Monday, May 22, 2023 | TOTAL INVALIDATION PROCESSED BY THE IB |
| Friday, October 20, 2023 | NEW REPRESENTATIVE AT IB RECEIVED |
| Sunday, December 31, 2023 | NEW REPRESENTATIVE AT IB RECEIVED |
| Friday, March 14, 2025 | DEATH OF INTERNATIONAL REGISTRATION |
| Friday, March 14, 2025 | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED |